Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 12/20 | 0.90 |
| ▸ | MAPT | P10636 | 4/20 | 0.88 |
| ▸ | GAA | P10253 | 1/20 | 0.88 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | MAOA | P21397 | 4/20 | 0.68 |
| ▸ | MAOB | P27338 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10624579 | 0.96 | ALDH2 (0.86) | ALDH2MAPTGAAMEN1KMT2A | |
| SCHEMBL10624708 | 0.95 | ALDH2 (1.00) | ALDH2MAPTGAAMEN1KMT2A | |
| SCHEMBL10620446 | 0.94 | ALDH2 (0.83) | ALDH2MAPTGAAMEN1KMT2A | |
| SCHEMBL8983972 | 0.93 | MAPT (1.00) | ALDH2MAPTGAAMEN1KMT2A | |
| SCHEMBL4261437 | 0.89 | MAPT (0.80) | ALDH2MAPTGAAMEN1KMT2A | |
| SCHEMBL11551965 | 0.89 | MEN1 (0.75) | ALDH2MAPTGAAMEN1KMT2A | |
| SCHEMBL4095148 | 0.88 | MAPT (0.87) | ALDH2MAPTGAAMEN1KMT2A | |
| SCHEMBL4094445 | 0.84 | ALDH2 (0.88) | ALDH2MAPTGAAMEN1KMT2A | |
| SCHEMBL11016377 | 0.84 | ALDH2 (0.89) | ALDH2MAPTGAAMAOAMAOB | |
| SCHEMBL12238017 | 0.83 | MAPT (0.74) | ALDH2MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158810-B2 | ALDH-2 inhibitors in the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2254878-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | Gilead Palo Alto, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-2231149-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV Therapeutics Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2009094028-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | AMYGDALA NEUROSCIENCES, INC. | 2009-05-14 | — | — | US | disclosed |
| WO-2009061924-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-2046769-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2008014497-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 5/4885MAPT 1815/4885GAA 1106/4885 |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 5/4885MAPT 1815/4885GAA 1106/4885 |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 4/4885MAPT 1778/4885GAA 937/4885 |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | ALDH2, ALDH1A2, ALDH1A1 | ALDH2 1/4885MAPT 2549/4885GAA 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.